Key Points
- Director Brian Posner purchased 2,500 Dyne Therapeutics shares at $16.00 each, investing $40,000 and increasing his direct ownership by 10.2% to 27,000 shares.
- Dyne reported quarterly EPS of -$1.08, missing the consensus estimate of -$0.75. Analysts expect a full-year loss of approximately $3.59 per share.
- Institutional investors own 96.68% of the company, while analysts maintain a “Moderate Buy” consensus rating with an average price target of $33.07, despite several recent target-price reductions.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Brian Posner purchased 2,500 shares of the business's stock in a transaction that occurred on Friday, October 2nd. The stock was acquired at an average price of $16.00 per share, for a total transaction of $40,000.00. Following the acquisition, the director directly owned 27,000 shares of the company's stock, valued at $432,000. This trade represents a 10.20% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.
Dyne Therapeutics Price Performance
DYN opened at $15.40 on Wednesday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 52-week low of $12.77 and a 52-week high of $27.31. The company has a 50 day moving average of $22.10 and a two-hundred day moving average of $20.52. The company has a market cap of $2.88 billion, a P/E ratio of -4.62 and a beta of 1.12.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts expect that Dyne Therapeutics, Inc. will post -3.59 earnings per share for the current year.
Institutional Investors Weigh In On Dyne Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Dyne Therapeutics during the 2nd quarter worth $275,500,000. Jupiter Topco LLC purchased a new position in Dyne Therapeutics in the 2nd quarter valued at about $266,634,000. Perceptive Advisors LLC boosted its position in Dyne Therapeutics by 543.7% in the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company's stock valued at $68,048,000 after buying an additional 2,938,500 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Dyne Therapeutics during the second quarter valued at about $49,604,000. Finally, Palo Alto Investors LP acquired a new stake in shares of Dyne Therapeutics during the second quarter valued at about $36,591,441. 96.68% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the company. Wall Street Zen downgraded Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. Jefferies Financial Group restated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. HC Wainwright decreased their target price on Dyne Therapeutics from $50.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, September 30th. Royal Bank Of Canada lowered their target price on Dyne Therapeutics from $35.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, September 9th. Finally, Chardan Capital reiterated a "buy" rating and set a $38.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $33.07.
Get Our Latest Report on DYN
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company's research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.
Dyne's development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
